• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    AC Immune S.A. (NQ: ACIU )

    3.630 +0.030 (+0.83%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 122,934
    Open 3.640
    Bid (Size) 3.410 (2)
    Ask (Size) 3.970 (13)
    Prev. Close 3.600
    Today's Range 3.560 - 3.740
    52wk Range 2.200 - 5.140
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
    From AC Immune SA
    Via GlobeNewswire
    RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -22.60%
    -22.60%
    1 Month
    -11.03%
    -11.03%
    3 Month
    +50.00%
    +50.00%
    6 Month
    -13.57%
    -13.57%
    1 Year
    +18.63%
    +18.63%

    More News

    Read More
    Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
    From AC Immune SA
    Via GlobeNewswire
    Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024
    Via InvestorPlace
    Gold Down Over 1%; AC Immune Shares Spike Higher
    Via Benzinga
    Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
    Via Benzinga
    Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge
    Via Benzinga
    Exposures Fossil Fuels
    Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?
    Via InvestorPlace
    Why Is Safe & Green Development (SGD) Stock Down 5% Today?
    Via InvestorPlace
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    Why Is AC Immune (ACIU) Stock Up 45% Today?
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
    From AC Immune SA
    Via GlobeNewswire
    ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    AC Immune Announces Upcoming Presentations at AD/PD™ 2024
    From AC Immune SA
    Via GlobeNewswire
    AC Immune to Regain Global Rights to Crenezumab and Semorinemab
    From AC Immune SA
    Via GlobeNewswire
    AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
    From AC Immune SA
    Via GlobeNewswire
    AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.